GSK3 polypeptides
US6465231B2 · kind B2 · utility
12Cited by
1References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2001 |
| Grant date | Oct 15, 2002 |
| Priority date | — |
| Expiry date | Jul 25, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.